The global preimplantation genetic testing market size is expected to reach USD 1.28 billion by 2030, growing at 7.0% CAGR from 2023 to 2030, as per the new report by Grand View Research, Inc. Recent technological advancements in testing have changed the current practice of prenatal screening and early detection of chromosomal abnormalities in an embryo. Moreover, the introduction of novel technologies such as NGS, PCR, and FISH is expected to drive market growth over the forecast period.
Growing awareness about genetic diseases and novel techniques for the detection of chromosomal abnormalities and embryo screening for successful IVF holds growth prospects for this vertical over the forecast period. Key market players and service providers such as COOPER SURGICAL, INC. are running awareness campaigns to promote an increased understanding of the diseases and screening of these diseases at the early stages. Such favorable initiatives are expected to increase the demand for PDT in IVF procedures globally.
The increasing adoption of in vitro fertilization (IVF) technique consequently upsurges the utilization of preimplantation genetic testing (PGT). These techniques are advantageous in allowing the development of a healthy fetus and preventing the risk of selective pregnancy termination. Hence, PGT acts as an addendum to assisted reproductive technology.
Moreover, the increased risk of genetic disease in newborns and complications associated with IVF procedures push healthcare providers to recommend PGT. For instance, according to the CDC, in the U.S., about 6,000 babies are born with Down syndrome each year. It is the most common chromosomal condition diagnosed in newborns in the country. Moreover, the high risk associated with aged pregnancy further increases the adoption of PGT worldwide.
Key companies are involved in developing novel methods and solutions to carry out preimplantation genetic diagnosis and screening. To maintain their significant share in the revenue in the coming years, these participants are undertaking strategic initiatives. The strategic undertakings include regional expansion, collaborative development, and new product developments.
For instance, in October 2022, Ovation Fertility and Genomic Prediction partnered to expand genetic testing services by using the LifeView PGT platform for PFT. Moreover, in April 2022, Clevergene received PCPNDT for prenatal genetic testing. The company aimed to expand its services in preimplantation genetic screening and non-invasive prenatal testing.
Request a free sample copy or view report summary: Preimplantation Genetic Testing Market Report
Based on procedure, the PGD segment dominated the preimplantation genetic testing industry with a revenue share of 77.0% in 2022
Based on product, reagent & consumables segment accounted for the largest revenue share in 2022, due to increasing demand for technologically advanced tests
The polymerase chain reaction segment accounted for the largest revenue share in 2022. PCR assures high probabilities of getting a large number of copies of a particular stretch of the genome, making further analysis possible and easy
Based on application, the aneuploidy screening segment dominated the preimplantation genetic testing industry in terms of revenue share in 2022, followed by the HLA typing segment
The hospital segment accounted for the highest revenue share in 2022, owing to improved healthcare facilities and a large number of IVF procedures
Asia Pacific is anticipated to witness the fastest CAGR over the forecast period. China and Japan are major countries in the region that continue to create advancements in reproductive health along with other healthcare disciplines
Grand View Research has segmented the global preimplantation genetic testing market based on procedure, product, application, technology, end-use, and region:
Preimplantation Genetic Testing Procedure Outlook (Revenue, USD Million, 2018 - 2030)
PGD
PGS
Preimplantation Genetic Testing Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents and Consumables
Instruments
Software
Preimplantation Genetic Testing Technology Outlook (Revenue, USD Million, 2018 - 2030)
Next Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Fluorescent In-Situ Hybridization (FISH)
Others
Preimplantation Genetic Testing Application Outlook (Revenue, USD Million, 2018 - 2030)
Chromosomal Abnormalities
X-linked Diseases
Embryo Testing
Aneuploidy Screening
HLA Typing
Other Applications
Preimplantation Genetic Testing End-use Outlook (Revenue, USD Million, 2018 - 2030)
Fertility Centers
Hospitals
Diagnostic Centers
Research Centers and Academic Labs
Preimplantation Genetic Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Preimplantation Genetic Testing Market
Quest Diagnostics Incorporated
Natera, Inc.
COOPER SURGICAL, INC.
Genea Pty Limited.
Invitae Corporation
Laboratory Corporation of America Holdings
Thermo Fisher Scientific Inc.
Bioarray S.L.
Illumina, Inc.
Igenomix
RGI
F. Hoffmann-La Roche Ltd
"The quality of research they have done for us has been excellent..."